厄贝沙坦对糖尿病肾病患者血ADM的影响  

The Effect of Irbesartan on Serum ADM in Early Diabetics Nephropathy

作　　者：李勤学 田改生 

机构地区：[1]包钢职工医院老年病科,内蒙古包头014010

出　　处：《内蒙古医学杂志》2012年第8期922-923,共2页Inner Mongolia Medical Journal

摘　　要：目的:观察厄贝沙坦对糖尿病肾病患者血ADM的影响。方法:早期糖尿病肾病患者66例,随机分为对照组(30例)、厄贝沙坦组(36例),进行3个月临床观察,两组患者均于治疗前后测血ADM浓度及UAER。结果:①对照组治疗前后血ADM浓度及UAER差异无统计学意义(P>0.05)。②厄贝沙坦组治疗后血ADM浓度及UAER较治疗前显著下降(P<0.05)。③血ADM与UAER呈正相关(r=0.723,P<0.05)。结论:①血ADM可能在糖尿病肾病发病中起重要作用。②厄贝沙坦可能降低血ADM起到肾脏保护作用。Objective：To investigate the effect of irbesartan on serum adrenomedullin（ADM） level in early diabetic nephropathy（DN）.Method：66 cases of patients with early DN were randomly divided into two groups： control group（30 cases） and irbesartan group（36 cases）.After 3-month treatment,Serum ADM levels and UAER of 66 cases were detected before and after treatment.Result：①After 3-month treatment,Serum ADM levels and UAER were no significantly increased compared with before in control group （P0.05）.②ADM levels and UAER were reduced obviously in irbesartan group（P0.05）.③Serum ADM levels was highly correlated with UAER（r=0.723,P0.05）.Conclusion：①ADM was probably involved in the process of pathophysiology in diabetic nephropathy.②Using irbesartan for reducing ADM can protect the kidney function of early diabetic.

关 键 词：糖尿病肾病 肾上腺髓质素 厄贝沙坦 

分 类 号：R587.1[医药卫生—内分泌]